Neo Ivy Capital Management Biocryst Pharmaceuticals Inc Transaction History

Neo Ivy Capital Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 24, 2023	BUY	$10.5 - $14.2 $172,053 - $232,681	16,386 New	16,386 $188,000
Q2 2022 Aug 16, 2022	SELL	$7.89 - $17.88 $3,676 - $8,332	-466 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $5,386 - $9,208	466 New	466 $8,000
Q3 2021 Nov 16, 2021	SELL	$14.21 - $17.65 $249,286 - $309,633	-17,543 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $29,298 - $53,168	3,084 Added 21.33%	17,543 $277,000
Q1 2021 Oct 07, 2021	BUY	$7.37 - $13.61 $106,562 - $196,786	14,459 New	14,459 $147,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.